Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 18/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 0.86 |
| ▸ | NPC1 | O15118 | 1/20 | 0.78 |
| ▸ | NSD2 | O96028 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.78 |
| ▸ | PKM | P14618 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | RAB9A | P51151 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9580683 | 1.00 | INSR (1.00) | INSRAPPNPC1NSD2MAPT | |
| Iodide SCHEMBL7028400 | 0.99 | INSR (0.97) | INSRAPPNPC1NSD2MAPT | |
| Iodide SCHEMBL29757617 | 0.99 | INSR (0.97) | INSRAPPNPC1NSD2MAPT | |
| Bromide SCHEMBL22598035 | 0.99 | INSR (0.97) | INSRAPPNPC1NSD2MAPT | |
| Bromide SCHEMBL22598036 | 0.99 | INSR (0.97) | INSRAPPNPC1NSD2MAPT | |
| Iodide SCHEMBL5679445 | 0.99 | INSR (0.97) | INSRAPPNPC1NSD2MAPT | |
| SCHEMBL2442132 | 0.92 | APP (1.00) | INSRAPPNPC1NSD2MAPT | |
| SCHEMBL2442135 | 0.92 | APP (1.00) | INSRAPPNPC1NSD2MAPT | |
| SCHEMBL17026626 | 0.91 | APP (0.98) | INSRAPPNPC1NSD2MAPT | |
| SCHEMBL29409742 | 0.91 | APP (0.98) | INSRAPPNPC1NSD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11215559-B2 | Thallium doped gadolinium chalcogenide nanocomposite | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-04 | — | — | US | disclosed |
| US-11209365-B1 | Thallium-gadolinium-chalcogenide nanodot composition | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-28 | — | — | US | disclosed |
| US-11209366-B1 | Quantum dot nanocomposite containing benzothiazolium | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-28 | — | — | US | disclosed |
| US-20210381974-A1 | QUANTUM DOT NANOCOMPOSITE CONTAINING BENZOTHIAZOLIUM | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-09 | — | — | US | disclosed |
| US-20210381973-A1 | THALLIUM-GADOLINIUM-YTTRIUM NANODOT COMPOSITION | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-09 | — | — | US | disclosed |
| US-20210341388-A1 | THALLIUM DOPED GADOLINIUM CHALCOGENIDE NANOCOMPOSITE | KING ABDULAZIZ UNIVERSITY (SA) | 2021-11-04 | — | — | US | disclosed |
| US-11143592-B2 | Method of detecting antimony ions and method of removing antimony ions using a fluorescent nanocomposite | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-12 | — | — | US | disclosed |
| US-20210054269-A1 | FLUORESCENT NANOCOMPOSITE AND A METHOD OF DETECTING ANTIMONY IONS | KING ABDULAZIZ UNIVERSITY (SA) | 2021-02-25 | — | — | US | disclosed |
| US-10823674-B1 | Antimony adsorbent | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-03 | — | — | US | disclosed |
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2012-02-09 | — | — | US | disclosed |
| US-5242892-A | With 5-aminolevulinic acid | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1993-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | SNCA, PSEN1, CDR2 | INSR 3376/4885APP 15/4885NPC1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.